Skip to content
OpenCapital
Get started

Relmada Therapeutics, Inc. RLMD Temporary differences related to Texas Margin Tax

Temporary differences related to Texas Margin Tax at other companies

Neuropace, Inc. logo
Neuropace, Inc.NPCE
——

Other financials

Income statement

See full
Operating income-$19.5M-6.8%
Net income-$19.1M-8.5%
EPS (diluted)-$0.22+62.1%

Balance sheet

See full
Cash & equivalents$9.8M+750%
Total debt$104.1M-40.4%
Total equity$218.7M+875%
Total assets$235.4M+750%

Cash flow

See full
Operating cash flow-$15.1M+16.6%

Valuation

See full
Market cap$677.17M+2,907%

Returns & leverage

See full
Return on equity-48.8%-20.0pp
Debt / equity0.9×0.0×
Current ratio18.3×+13.0×

Where this comes from

Reported directly by Relmada Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals.

The official record: Relmada Therapeutics, Inc.’s 10-K, filed March 19, 2026, on SEC EDGAR. View the filing →

Ask your AI about Relmada Therapeutics, Inc.'s temporary differences related to texas margin tax.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Relmada Therapeutics, Inc.'s temporary differences related to texas margin tax?
Relmada Therapeutics, Inc. (RLMD) reported temporary differences related to texas margin tax of $1.61M in Q4 2025.
How has Relmada Therapeutics, Inc.'s temporary differences related to texas margin tax changed year-over-year?
Relmada Therapeutics, Inc.'s temporary differences related to texas margin tax increased by 15.0% year-over-year, from $1.4M to $1.61M.
What is the long-term trend for Relmada Therapeutics, Inc.'s temporary differences related to texas margin tax?
Over 5 years (2020 to 2025), Relmada Therapeutics, Inc.'s temporary differences related to texas margin tax has grown at a 20.0% compound annual growth rate (CAGR), from $645K to $1.61M.